The dynamics of T-cell immunity in patients with TBI after neuroprotective therapy.
Kyrgyz State Medical Academy named after I.K. Achunbaev, Neurology and Medical Genetics Department, Bishkek, Kyrgyzstan
The aim is a prospective analysis of the results of laboratory studies of conservative treatment of 63 patients with traumatic brain injury of moderate severity. Of these, 21 patients (study group), along with the treatment provided by medical standards prescribed drug cerebrolysin. In the control group (42 people), patients received only standard therapy. We evaluated the dynamics of indicators of T-cell immunity. Treatment added with cerebrolysin led to positive changes among the indicators of cellular immunity and partial correction arising after TBI T-cell immunodeficiency due to an increase of the percentage of CD3+ and CD4+ T-cell subpopulations.